Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1R) agonists are more effective and have fewer side effects. GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing A beta deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD. However, this needs to be verified by further clinical trials. This study aims to summarize the current information on the mechanisms and effects of GLP-1R agonists in AD.
基金：
Scientific Research Foundation of the Ministry of Education of China; Scientific Research Foundation of Postdoctoral Department of Heilongjiang Province; [2021JH019]; [LBH-Q21025]
第一作者单位：[1]Harbin Med Univ, Affiliated Hosp 2, Dept Orthoped, Div Orthoped, Harbin, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Du Haiyang,Meng Xiaoyu,Yao Yu,et al.The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease[J].FRONTIERS IN ENDOCRINOLOGY.2022,13:doi:10.3389/fendo.2022.1033479.
APA：
Du, Haiyang,Meng, Xiaoyu,Yao, Yu&Xu, Jun.(2022).The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease.FRONTIERS IN ENDOCRINOLOGY,13,
MLA：
Du, Haiyang,et al."The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease".FRONTIERS IN ENDOCRINOLOGY 13.(2022)
